Highlights
Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.
- Cancer of the Pancreas
- Genetics and molecular alterations in pancreatic cancer
- Are we making progress in surgery of the pancreas?
- Adjuvant and neoadjuvant treatment options in resectable and borderline resectable pancreatic cancer
- Treatment approaches in locally advanced unresectable pancreatic cancer
- Improving the outcomes of patients with metastatic pancreatic cancer
- Bile Duct Cancer
- Molecular alterations in bile duct cancer
- New agents and strategies on the horizon in bile duct cancer
- The management of locally advanced bile duct cancer
- Meet the Expert Presentations
- New endoscopic diagnostic and therapeutic technique screening tools: NBI, chromoendoscopy, and other options - How do they help us?
- Advances in surgery of rectal cancer
- New developments in radiation oncology
- Progress in anal cancer
- Carcinoma of unknown origin
- How to classify NETs and NECs?
- Progress in GIST
- What to do with a malignant colon and rectal polyp?
ESMO Session: Focus on Young Medical Oncologists
- New Concepts in Clinical Trials and Therapeutics
- Clinical interpretation and validity of clinical trials: When do they become practice-changing?
- Gender and race concepts in clinical trials
- Tumor agnostic trials and approaches
- Studying value and health economics
- Studying biosimilars: What is needed and what is the role of biosimilars?
- Esophageal and Gastric Cancers
- Unraveling the molecular taxonomy in esophageal and gastric cancer
- Barrett's esophagus: Role of advanced endoscopy in the diagnosis and treatment
- Management of squamous cell cancer of the esophagus
- Definitive CRT or neoadjuvant therapy followed by surgery in esophageal cancer
- Locally advanced GE junction cancer: CRT or perioperative CT
- Surgery in oligometastatic gastric cancer?
- Where are we with checkpoint inhibitors in metastatic gastric cancer?
- New targeted agents in metastatic gastric cancer
- Relevant Pathways in GI Cancer: How Relevant and How to Approach Them?
- The HER2 pathway
- The FGFR pathway
- Protein fusions in GI cancers
- NGS testing for all patients with GI cancers?
- Hepatocellular Carcinoma
- How to integrate new agents in HCC
- Locoregional treatment for HCC
- Liver transplantation for HCC
- Multidisciplinary tumor board on HCC
- Expert Highlights: What is New in this Disease in 2021?
- What is new in NETs?
- What is new in anal cancer?
- What is new in bile duct cancer?
- Prevention and Screening of Colon Cancer
- Genetic testing for familial and hereditary colorectal cancer
- Screening for colon cancer: What has been achieved in 2021 and new prospects?
- Will chemoprevention become a reality?
- Multimodality Therapy for Rectal Cancer
- Imaging in rectal cancer
- Rectal cancer after neoadjuvant therapy with complete clinical response: Surgery or watchful waiting
- New prospects in rectal cancer surgery
- Adjuvant chemotherapy or neoadjuvant chemotherapy in rectal cancer
- Total neoadjuvant treatment in rectal cancer
- A role for neoadjuvant chemotherapy without radiotherapy
- The strategy in synchronous liver metastases of rectal cancer
- Molecular Biology in CRC
- How to approach a patient with BRAF mutant tumor?
- Current status and perspectives on liquid biopsies in GI cancer
- Is circulating tumor DNA relevant in stage II colon cancer?
- Will microresidual disease assessed by circulating tumor DNA become the new decision indicator of adjuvant treatment?
- Practical implications of the molecular and immunologic classifications in CRC
- Is broad NGS testing useful in my patients with metastatic colorectal cancer?
- Keynote Lectures
- The microbiome in GI cancers
- Novel immuno-oncology mechanisms and approaches in GI cancers: Where are we?
- Should DPD deficiency be searched before starting 5FU?
- Relevant drug interactions in GI oncology
- How to look for minimal residual disease
- Multidisciplinary Tumor Boards
- Molecular and hereditary tumor board
- The challenging patient with HCC
- The challenging patient with colorectal cancer
- Immune Mechanisms and Immune Therapy in GI Cancer
- How to improve the results with IO agents in MSI GI cancer
- Biomarkers for checkpoint inhibitors in GI cancer
- How can we increase the immunogenicity in MSS CRC?
- Are we making progress with IO in pancreatic cancer?
- The link between the immune microenvironment and outcome in colorectal cancer
- Colorectal Cancer
- Endoscopic treatment of small lesions
- Updates on treatment algorithms in metastatic CRC in 2021
- Chemorefractory colorectal cancer
- Can we refine the selection for adjuvant treatment in stage II colon cancer?
- Can we refine the selection for adjuvant treatment in stage III colon cancer?
- Clinical Updates
- When and how to select for debulking and HIPEC in peritoneal carcinomatosis
- Liver resection of liver metastases
- Role of robotic surgery